AbbVie (4AB) Stock Price & Analysis
4AB Stock Chart & Stats
- Day’s Range
- EUR 253.00 - EUR 259.70
- 52-Week Range
- EUR 162.85 - EUR 270.70
- Previous Close
- EUR 262.80
- Volume
- N/A
- Average Volume (3M)
- 897
- Market Cap
- EUR 458.82B
- Enterprise Value
- EUR 533.71B
- Total Cash (Recent Filing)
- EUR 10.77B
- Total Debt (Recent Filing)
- EUR 80.90B
- Price to Earnings (P/E)
- 50.3
- Beta
- 0.25
- Next Earnings
- Feb 03, 2027 (Est.)
- EPS Estimate
- 3.46
- Next Dividend Ex-Date
- Jan 15, 2027
- Dividend Yield
- 2.31%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
AbbVie converts earnings into substantial cash, with free cash flow nearly matching operating cash flow and net income. This supports research investment, dividends, acquisitions and debt reduction, giving the business meaningful capacity to fund growth while maintaining strong operating resilience.
Immunology Franchise Strength
Skyrizi and Rinvoq are demonstrating strong adoption, differentiated clinical profiles and expanding demand across immunology. Their scale, patient share and additional indications provide a durable growth engine that can support revenue progression beyond legacy product declines.
Broad Pipeline And Portfolio Diversification
AbbVie is extending its pipeline across immunology, respiratory disease, dermatology, oncology and neuroscience rather than relying on one therapeutic area. New clinical programs and the Apogee assets broaden future launch opportunities and improve portfolio durability over time.
Bears Say
High Leverage And Balance-sheet Risk
AbbVie operates with a heavy debt burden relative to its capital base, and prior negative equity highlights balance-sheet instability. Sustained cash generation is needed to preserve flexibility, reduce refinancing exposure and fund acquisitions without constraining investment.
Legacy Product Erosion And Competition
Biosimilar competition, government pricing and share pressure are reducing important established franchises. These declines can offset growth from newer products, create earnings volatility and require continued successful launches to maintain the company’s overall growth trajectory.
Pricing, Access And Regulatory Execution Risk
Regulatory timing, payer access and upcoming IRA pricing can delay adoption or reduce economics for growth products. These pressures may weigh on near-term commercialization and require successful execution across approvals, reimbursement and lifecycle expansion plans.
4AB FAQ
What was AbbVie’s price range in the past 12 months?
What is AbbVie’s market cap?
When is AbbVie’s upcoming earnings report date?
How were AbbVie’s earnings last quarter?
Is AbbVie overvalued?
Does AbbVie pay dividends?
What is AbbVie’s EPS estimate?
How many shares outstanding does AbbVie have?
What happened to AbbVie’s price movement after its last earnings report?
Which hedge fund is a major shareholder of AbbVie?
What is the TipRanks Smart Score and how is it calculated?
AbbVie Stock Smart Score
Company Description
AbbVie
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael
- Employees
- 57,000
- Website
- www.abbvie.com
- Address
- 1 North Waukegan Road, North Chicago, IL, 60064-6400, US
AbbVie (4AB) Earnings & Revenues
4AB Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. AbbVie reported double-digit revenue growth, earnings above guidance, multiple raised full-year outlooks, strong performance from Skyrizi, Rinvoq and neuroscience products, substantial pipeline progress and increased shareholder returns. The principal negatives were declines in Humira, Imbruvica and Juvéderm, aesthetics market pressure, regulatory timing for Boey, upcoming IRA pricing for Vraylar and ongoing competitive and access considerations. The highlights significantly outweighed the lowlights.
View all DE:4AB earnings summaries4AB Net sales Breakdown
- 47.36% Immunology
- 15.97% Neuroscience
- 11.86% Other Key Products
- 11.64% Oncology
- 13.17% Other
4AB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 6 | 1 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 12 | 0 | 0 |
